Orphagen Pharmaceuticals

About Orphagen Pharmaceuticals

Orphagen Pharmaceuticals is focused on pioneering small molecule therapies to address cancer and other serious diseases. Their mission involves translational drug discovery and development with novel targets to create first-in-class therapeutics, targeting unexplored areas through innovative drug candidates that block novel members of the nuclear receptor superfamily.

Products & Services

OR-449 for Oncology:A therapy targeting various cancers including adrenal cancer, head & neck, and other squamous cancers, with both tumor-specific and precision therapy opportunities.

OR-812 for IBD:A differentiated oral small molecule therapy for ulcerative colitis and Crohn's disease.

RORβ Antagonists:Drug candidates targeting novel members of the nuclear receptor superfamily for various therapeutic applications.

Specialties

Small Molecule Therapies Nuclear Receptor Programs Oncology Inflammatory Bowel Disease (IBD) Translational Drug Discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: SBIR Grant T: - FT: SBIR Grant	A: 1700000 MR: - FA: up to $1.7 million FAN: 1700000	D: 2024-12-09 FD: 2024-12-09	1 investors

SBIR Grant Latest

2024-12-09

$1.7M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Scott Thacher

Founder and Chief Executive Officer

P

Paul Crowe

Vice President of Drug Discovery

J

Jukka Muhonen

Vice President of Business Development

A

Andrew Dorr

Chief Medical Officer

D

Daniel von Hoff

N

Neil Raheja

Director of Chemistry

View 14 more team members with Pro

Unlock Full Team Directory

Recent News